A high percentage of insider ownership can be a sign of company health. Log in to see them here or sign up to get started. Since then, ODT shares have … View institutional ownership trends for Odonate Therapeutics. Copyright © 2021 MarketWatch, Inc. All rights reserved. Many technical investors use Odonate Therapeutics stock news … On February 23, 2021, Odonate Therapeutics, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sale Agreement”) with Jefferies LLC (the “Agent”), pursuant to which … Learn everything you need to know about successful options trading with this three-part video course. They contain too much fluff… You only learn from one expert… And the tactics lose their power after a couple of years too. 2 equities research analysts have issued 12 month price targets for Odonate Therapeutics' shares. Odonate Therapeutics NASDAQ Updated Mar 2, 2021 10:44 PM. By using this site you agree to the MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Odonate Therapeutics has received 57.22% “underperform” votes from our community. View which stocks have been most impacted by COVID-19. Looking for new stock ideas? Find real-time ODT - Odonate Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. ODT 19.10 0.25 (1.29%). Specifically, they have bought $11,044,885.00 in company stock and sold $0.00 in company stock. Get daily stock ideas top-performing Wall Street analysts. The company was founded in March 2013 and is headquartered in San Diego, CA. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Odonate Therapeutics share forecasts, stock … The company can be reached via phone at 858-731-8180 or via email at [email protected]. Indicate by check mark if the registrant is a well-known seasoned … Intraday Data provided by FACTSET and subject to terms of use. One share of ODT stock can currently be purchased for approximately $17.88. Odonate Therapeutics has received a consensus rating of Buy. American Eagle Turns in Beats, Recovery In Progress? As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. ODT Final Deadline Today: Rosen, Top Ranked National Investor Attorneys, Reminds Odonate Therapeutics, Inc. Investors of Important November 16 Deadline in Securities Class Action - ODT … Learn more. View breaking news headlines for ODT stock from trusted media outlets at MarketBeat. On average, they anticipate Odonate Therapeutics' stock price to reach $50.00 in the next year. Here's Why Odonate Therapeutics Stock Jumped 70.7% in June Cory Renauer | Jul 9, 2019 Shares of ODT can be purchased through any online brokerage account. Identify stocks that meet your criteria using seven unique stock screeners. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. View analyst ratings for Odonate Therapeutics or view top-rated stocks. Wall Street analysts have given Odonate Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Odonate Therapeutics Inc () Stock Market info Recommendations: Buy or sell Odonate Therapeutics stock? Find the latest news headlines from Odonate Therapeutics, Inc. Common Stock (ODT) at Nasdaq.com. Their forecasts range from $50.00 to $50.00. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Is there a better alternative to online courses? Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. The company issued 5,900,000 shares at $24.00-$27.00 per share. View the latest Odonate Therapeutics Inc. (ODT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Earnings for Odonate Therapeutics are expected to grow in the coming year, from ($3.74) to ($3.50) per share. View all of ODT's competitors. The P/E ratio of Odonate Therapeutics is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. In the past three months, Odonate Therapeutics insiders have bought more of their company's stock than they have sold. Get the latest news and real-time alerts from Odonate Therapeutics, Inc. (ODT) stock at Seeking Alpha. Business Wire - 6 months ago Odonate Therapeutics … Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, … Why Odonate Therapeutics (ODT) Stock Might be a Great Pick. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. This suggests a possible upside of 179.6% from the stock's current price. Subscriber Agreement & Terms of Use, Stock analysis for Odonate Therapeutics Inc (ODT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), The Boeing (BA), Bausch Health Companies (BHC), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), AbbVie (ABBV), Apellis Pharmaceuticals (APLS), Athenex (ATNX), BioCryst Pharmaceuticals (BCRX) and CRISPR Therapeutics (CRSP). FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm, FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm, DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm, FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action – ODT, FINAL DEADLINE NOTICE: Rosen, Global Investor Counsel, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action - ODT, SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm, SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.– ODT; IMPORTANT NOV. 16 DEADLINE- ODT, The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PT, ODT and LOOP, ODT, NNOX & GOCO Looming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Lead Plaintiff Deadlines, ODT STOCK ALERT: Zhang Investor Law Announces Securities Class Action Lawsuit Against Odonate Therapeutics, Inc. – ODT, LAWSUITS FILED AGAINST NNOX, ODT and GLNG - Jakubowitz Law Pursues Shareholders Claims, SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Odonate Therapeutics, Inc. and of Class Action Lawsuit and Upcoming Deadline – ODT, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. Fundamental company data provided by Zacks Investment Research. ODT | Complete Odonate Therapeutics Inc. stock news by MarketWatch. Get short term trading ideas from the MarketBeat Idea Engine. You may vote once every thirty days. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 View insider buying and selling activity for Odonate Therapeutics or or view top insider-buying stocks. Odonate Therapeutics employs 134 workers across the globe. Odonate Therapeutics (NASDAQ: ODT) shares were trading lower on Monday after the company announced the results from CONTESSA, a Phase 3 study of Tesetaxel, achieved the primary … Odonate Therapeutics, Inc. (NASDAQ:ODT) CEO Kevin C. Tang bought 275,784 shares of Odonate Therapeutics stock in a transaction dated Wednesday, December 23rd. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. (Add your “outperform” vote. Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT.". 3 More Reason’s Ethereum’s (ETH) Bull Market Is Far From Over, Marvell Technologies Stock Presents Opportunistic Pullback Levels, Splunk Stock Surges on Better-Than-Expected Results, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, Trade Alert: The Independent Director Of Odonate Therapeutics, Inc. (NASDAQ:ODT), Craig Johnson, Has Just Spent US$51k Buying A Few More Shares, 3 Beaten-Down Stocks Insiders Scooped Up as 2020 Ended. Shares of ODT stock … A high-level overview of Odonate Therapeutics, Inc. (ODT) stock. (Add your “underperform” vote.). Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. All rights reserved. Learn about financial terms, types of investments, trading strategies and more. The consensus among Wall Street equities research analysts is that investors should "buy" Odonate Therapeutics stock. The official website for Odonate Therapeutics is www.odonate.com. Cookie Notice (). Odonate Therapeutics has a P/B Ratio of 3.53. The stock was acquired at an … Compare Top Brokerages Here. Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, … ), Odonate Therapeutics has received 206 “underperform” votes.